Literature DB >> 17726263

Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas.

D M Heijink1, J H Kleibeuker, M Jalving, W Boersma-van Ek, J J Koornstra, J Wesseling, S de Jong.   

Abstract

BACKGROUND: TNF-Related Apoptosis Inducing Ligand (TRAIL) is a promising agent for the induction of apoptosis in neoplastic tissues. Important determinants of TRAIL sensitivity are two intracellular proteins of the TRAIL pathway, caspase-8 and its anti-apoptotic competitor cellular Flice-Like Inhibitory Protein (cFLIP).
METHODS: The aim of this study was to investigate basic expression of caspase-8 and cFLIP in normal colorectal epithelium (n=20), colorectal adenomas (n=66) and colorectal carcinomas (n=44) using immunohistochemistry performed on both sporadic and Hereditary Non-Polyposis Colorectal Cancer (HNPCC or Lynch syndrome)-associated adenomas and carcinomas.
RESULTS: Expression of both caspase-8 and cFLIP was similar in cases with sporadic and hereditary origin. Expression of caspase-8 in colorectal adenomas and carcinomas was increased when compared to normal colon tissue (P=0.02). Nuclear, paranuclear as well as cytoplasmic localizations of caspase-8 were detected. Immunohistochemistry revealed an upregulation of cFLIP in colorectal carcinomas in comparison to normal epithelium and colorectal adenomas (P<0.001). A large variation in the caspase-8/cFLIP ratio was observed between the individual adenomas and carcinomas.
CONCLUSION: Caspase-8 and cFLIP are upregulated during colorectal carcinogenesis. Upregulation of caspase-8 and/or downregulation of cFLIP may be interesting approaches to maximize TRAIL sensitivity in colorectal neoplasms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726263      PMCID: PMC4617989          DOI: 10.1155/2007/564605

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  10 in total

1.  Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.

Authors:  Donal P McLornan; Helen L Barrett; Robert Cummins; Ultan McDermott; Cliona McDowell; Susie J Conlon; Victoria M Coyle; Sandra Van Schaeybroeck; Richard Wilson; Elaine W Kay; Daniel B Longley; Patrick G Johnston
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

2.  Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.

Authors:  Heath A Elrod; Songqing Fan; Susan Muller; Georgia Z Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

Review 3.  Pathophysiological mechanisms of death resistance in colorectal carcinoma.

Authors:  Ching-Ying Huang; Linda Chia-Hui Yu
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

4.  Expression Level of Caspase Genes in Colorectal Cancer

Authors:  Milad Asadi; Dariush Shanehbandi; Touraj Asvadi Kermani; Zohreh Sanaat; Venus Zafari; Shahriyar Hashemzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

5.  Analysis of potential genes and pathways associated with the colorectal normal mucosa-adenoma-carcinoma sequence.

Authors:  Zhuoxuan Wu; Zhen Liu; Weiting Ge; Jiawei Shou; Liangkun You; Hongming Pan; Weidong Han
Journal:  Cancer Med       Date:  2018-04-16       Impact factor: 4.452

6.  Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer.

Authors:  Ana Luiza C de S L Oliveira; Raimundo Fernandes de Araújo Júnior; Thaís Gomes de Carvalho; Alan B Chan; Timo Schomann; Filippo Tamburini; Lioe-Fee de Geus-Oei; Luis J Cruz
Journal:  Pharmaceutics       Date:  2020-02-23       Impact factor: 6.321

7.  Fas ligand expression in lynch syndrome-associated colorectal tumours.

Authors:  Jan J Koornstra; Steven de Jong; Wietske Boersma-van Eck; Nynke Zwart; Harry Hollema; Elisabeth G E de Vries; Jan H Kleibeuker
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

8.  Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

Authors:  T Trarbach; M Moehler; V Heinemann; C-H Köhne; M Przyborek; C Schulz; V Sneller; G Gallant; S Kanzler
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

9.  Genetic polymorphisms of the CASP8 gene promoter may not be associated with colorectal cancer in Han Chinese from southwest China.

Authors:  Mei-Sheng Xiao; Le Chang; Wen-Liang Li; Yong-Sheng Du; Yue Pan; Deng-Feng Zhang; Yu Wen; Juan Luo; Xiao-Yan Li; Yong-Gang Yao
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

10.  A Gene-Based Machine Learning Classifier Associated to the Colorectal Adenoma-Carcinoma Sequence.

Authors:  Antonio Lacalamita; Emanuele Piccinno; Viviana Scalavino; Roberto Bellotti; Gianluigi Giannelli; Grazia Serino
Journal:  Biomedicines       Date:  2021-12-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.